The intravitreal injection: Variations in regulations, cost and reimbursement in Europe;Die intravitreale Injektion: Unterschiedliche Vorgaben, Kosten und Kostenerstattung in Europa

Spektrum der Augenheilkunde

Volumn 26, Issue 1, 2012, Pages 2-6

  Michels, S ^a   Becker, M ^a,d   Wachtlin, J ^b   Binder, S ^c  

^a TRIEMLI HOSPITAL   (Switzerland)

^b Sankt Gertrauden Hospital   (Germany)

^c KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Bevacizumab; Intravitreal injection; Ranibizumab; Reimbursement

Indexed keywords

EID: 84857332308     PISSN: 09304282     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00717-012-0072-2     Document Type: Review

References (18)

1. Brown DM, Michels M, Kaiser PK, et al. ANCHOR Study Group. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology. 2009 Jan; 116(1): 57-65. e5.
2. Rosenfeld PJ, Brown DM, Heier JS, et al. MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006 Oct 5; 355(14): 1419-31.
3. Mitchell P, Bandello F, Schmidt-Erfurth U, et al. RESTORE study group. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011 Apr; 118(4): 615-25.
4. Brown DM, Campochiaro PA, Singh RP, et al. CRUISE Investigators. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010 Jun; 117(6): 1124-33. e1.
5. Campochiaro PA, Heier JS, Feiner L, et al. BRAVO Investigators. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010 Jun; 117(6): 1102-1112. e1.
6. European Medicines Agency. Ranibizumab. Annex I. Summary of product characteristics. Available from: www. ema. europa. eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000715/WC500043546. pdf.
7. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol. 2009 Jul; 148(1): 43-58. e1.
8. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol. 2007 Apr; 143(4): 566-83.
9. Deutsche Ophthalmologische Gesellschaft. Neue Aspekte in der Therapie der neovaskulären altersabhängigen Makuladegeneration: Kriterien der Wiederbehandlung bei der Anti-VEGF Therapie. Available from: www. dog. org/wp-content/uploads/2009/09/Stellungnahme-AMD-Ergänzung-010411. pdf.
10. Empfehlung der Deutschen Ophthalmologischen Gesellschaft, der Retinologischen Gesellschaft und des Berufsverbandes der Augenärzte Deutschlands für die Durchführung von intravitrealen Injektionen (IVI). Available from: www. dog. org/wp-content/uploads/2009/09/DOG_Empfehlung_Intravitreale_Injektionen. pdf.
11. Heuer A, Mejer M, Neuhaus J. The National Regulation of Pharmaceutical Markets and the Timing of New Drug Launches in Europe. Available from: www. econstor. eu/bitstream/10419/27014/1/531160157. PDF.
12. Danzon, P. M., Wang, Y. R. and Wang, L. The impact of price regulation on the launch delay of new drugs - evidence from twenty-five major markets in the 1990s. Health Economics 2005, 14, 262-92.
13. National Insitute for Health and Clinical Excellence. Macular degeneration (age-related) - ranibizumab and pegaptanib (TA155). Available at: http://guidance. nice. org. uk/TA155.
14. Heimann H, Yang Y, Wachtlin J, Pauleikhoff D. Differences in the treatment of exudative age-related macular degeneration in Germany and Great Britain. Ophthalmologe. 2011 Jun; 108(6): 575-84.
15. Moshfeghi AA, Rosenfeld PJ, Flynn HW Jr, et al. Endophthalmitis after intravitreal anti-vascular endothelial growth factor antagonists: a six-year experience at a university referral center. Retina. 2011 Apr; 31(4): 662-8.
16. Chen E, Lin MY, Cox J, Brown DM. Retina. Endophthalmitis after intravitreal injection: the importance of viridans streptococci. 2011 Sep; 31(8): 1525-33.
17. Shah CP, Garg SJ, Vander JF, et al. Post-Injection Endophthalmitis (PIE) Study Team. Outcomes and risk factors associated with endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents. Ophthalmology. 2011 Oct; 118(10): 2028-34.
18. Albrecht M, Töpfer A. Erfolgreiches Changemanagement im Krankenhaus. Springer 2006.